1

투자심의 대상과제

RFP(지원분야)

투자심의 대상과제(과제번호)

신약 기반 확충연구

유효물질단계

RS-2023-00217242, RS-2023-00217266,

RS-2023-00217274, RS-2023-00217308,

RS-2023-00217324, RS-2023-00217370,

RS-2023-00217378, RS-2023-00217889,

RS-2023-00218195, RS-2023-00218433,

RS-2023-00218834

선도물질단계

RS-2023-00217381, RS-2023-00217408,

RS-2023-00217717, RS-2023-00217737,

RS-2023-00217783, RS-2023-00217969,

RS-2023-00217986, RS-2023-00218244,

RS-2023-00218315, RS-2023-00218351,

RS-2023-00218618, RS-2023-00218778,

RS-2023-00219269, RS-2023-00219308,

RS-2023-00219380

신약 R&D 생태계 구축 연구

후보물질단계

RS-2023-00217008, RS-2023-00217014,

RS-2023-00217095, RS-2023-00217215,

RS-2023-00217294, RS-2023-00217306,

RS-2023-00217478, RS-2023-00217674,

RS-2023-00217830, RS-2023-00217878,

RS-2023-00217918, RS-2023-00218182,

RS-2023-00218545, RS-2023-00218592,

RS-2023-00218641, RS-2023-00218767,

RS-2023-00218770, RS-2023-00218823,

RS-2023-00219249, RS-2023-00219324,

RS-2023-00219366, RS-2023-00219599

비임상단계

RS-2023-00217138, RS-2023-00217262,

RS-2023-00217346, RS-2023-00217372,

RS-2023-00217374, RS-2023-00217391,

RS-2023-00217541, RS-2023-00217692,

RS-2023-00218267, RS-2023-00218402,

RS-2023-00218894, RS-2023-00218925,

RS-2023-00219125, RS-2023-00219146,

RS-2023-00219365, RS-2023-00219493,

RS-2023-00219642

신약 임상개발

임상단계

(임상1상, 2상)

RS-2023-00217027, RS-2023-00217107,

RS-2023-00217175, RS-2023-00217291,

RS-2023-00218035, RS-2023-00218051,

RS-2023-00218347, RS-2023-00219060,

RS-2023-00219938

2

실사평가 안내

3

문의처

이메일

연락처

kddf_pm@kddf.org

02-6379-3083

4

참고사항